EFG International AG Acquires Shares of 40,543 Repligen Corporation $RGEN

EFG International AG acquired a new stake in Repligen Corporation (NASDAQ:RGEN) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 40,543 shares of the biotechnology company’s stock, valued at approximately $5,529,000. EFG International AG owned 0.07% of Repligen at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Price T Rowe Associates Inc. MD raised its position in Repligen by 31.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,599,061 shares of the biotechnology company’s stock valued at $753,603,000 after purchasing an additional 1,091,683 shares during the last quarter. United Capital Financial Advisors LLC purchased a new position in Repligen during the 3rd quarter worth $368,387,000. Opti Capital Management LP acquired a new position in Repligen in the fourth quarter valued at $2,399,209,000. Wasatch Advisors LP increased its stake in Repligen by 27.9% in the second quarter. Wasatch Advisors LP now owns 1,590,251 shares of the biotechnology company’s stock valued at $216,974,000 after purchasing an additional 346,720 shares during the period. Finally, Maverick Capital Ltd. purchased a new stake in shares of Repligen in the first quarter valued at about $178,946,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Repligen

In other news, CFO Jason K. Garland sold 733 shares of the stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total transaction of $106,285.00. Following the completion of the transaction, the chief financial officer directly owned 19,359 shares of the company’s stock, valued at approximately $2,807,055. This represents a 3.65% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 0.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on RGEN. Jefferies Financial Group reissued a “hold” rating and set a $142.00 price target on shares of Repligen in a report on Tuesday, May 5th. HSBC reduced their price objective on Repligen from $170.00 to $150.00 and set a “buy” rating for the company in a research note on Wednesday, June 3rd. Zacks Research raised Repligen from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 30th. Wolfe Research initiated coverage on Repligen in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $145.00 target price on the stock. Finally, Royal Bank Of Canada began coverage on Repligen in a report on Thursday, May 14th. They issued an “outperform” rating and a $160.00 target price on the stock. Three investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $166.43.

Repligen Stock Up 0.0%

Shares of NASDAQ:RGEN opened at $181.69 on Wednesday. The company has a market cap of $10.25 billion, a price-to-earnings ratio of 248.89, a PEG ratio of 3.31 and a beta of 1.03. The firm’s 50-day simple moving average is $149.17 and its 200-day simple moving average is $132.22. The company has a quick ratio of 7.64, a current ratio of 9.05 and a debt-to-equity ratio of 0.26. Repligen Corporation has a fifty-two week low of $100.99 and a fifty-two week high of $188.73.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.45 by $0.09. The firm had revenue of $204.13 million during the quarter, compared to analysts’ expectations of $201.59 million. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The firm’s revenue for the quarter was up 11.9% on a year-over-year basis. During the same period in the prior year, the company posted $0.26 earnings per share. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. As a group, equities research analysts predict that Repligen Corporation will post 2.06 earnings per share for the current year.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.